Cyclacel Pharmaceuticals (NASDAQ:BGMS) Issues Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) announced its earnings results on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, Zacks reports.

Cyclacel Pharmaceuticals Stock Performance

Shares of Cyclacel Pharmaceuticals stock traded down $0.05 during midday trading on Friday, reaching $1.00. 14,800 shares of the company’s stock traded hands, compared to its average volume of 68,712. The stock has a market capitalization of $5.50 million, a P/E ratio of -0.22 and a beta of -0.49. Cyclacel Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $34.65. The firm has a 50 day moving average of $0.99.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.